Reports Q3 revenue $3.3M vs. $3.6M last year. “Behind every breast reconstruction is a woman overcoming cancer,” said Randy Mills, CEO of Elutia (ELUT). “Incredibly, infection remains one of the biggest barriers to recovery, impacting 15-20% of reconstruction cases. Our antibiotic-eluting technology is designed to prevent infection from occurring in the first place. The Elutia CRU is laser-focused on this goal, fully resourced, and moving fast to deliver a game-changing solution that helps women everywhere thrive without compromise.”
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELUT: